Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer - Reply

被引：1
|
作者：
Buzdar, AU [1 ]
Theriault, RL [1 ]
Hunt, KK [1 ]
Hortobagyi, GN [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 30期
关键词：
D O I：
10.1200/JCO.2005.03.2797
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7760 / 7761
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer
    Ahluwalia, MS
    Daw, HA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7759 - 7760
  • [2] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    CANCER RESEARCH, 2012, 72
  • [3] Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer - In Reply
    Cianfrocca, Mary
    ONCOLOGIST, 2006, 11 (05): : 534 - 534
  • [4] HER-2-positive metastatic breast cancer: trastuzumab and beyond
    Metro, Giulio
    Mottolese, Marcella
    Fabi, Alessandra
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2583 - 2601
  • [5] Docetaxel, carboplatin and weekly trastuzumab are active as neoadjuvant therapy in operable HER2-positive breast cancer
    Kolberg, H. -C.
    Akpolat-Basci, L.
    Otterbach, F.
    Drumm, A.
    Tirier, C.
    BREAST, 2011, 20 : S74 - S74
  • [6] Remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin in breast cancer
    Mross, K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (05) : 296 - 297
  • [7] HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy
    Jackisch, Christian
    ONCOLOGIST, 2006, 11 : 34 - 41
  • [8] Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
    Levaggi, A.
    Poggio, F.
    Lambertini, M.
    D'Alonzo, A.
    Giraudi, S.
    Bighin, C.
    Blondeaux, E.
    Pastorino, S.
    Abate, A.
    Iacono, G.
    Vaglica, M.
    Conte, B.
    Pronzato, P.
    Del Mastro, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [10] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
12345